Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048917 · ClinicalTrials.gov registry record · Phase 1
Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies
A Phase 1 study of Lung Cancer and Head and Neck Cancer, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
- 10
- Study locations
NCT02048917: Completed Phase 1 study of Lung Cancer and Head and Neck Cancer, sponsored by University of Kentucky.
NCT02048917 is a Phase 1 study of Lung Cancer and Head and Neck Cancer that has completed, run by University of Kentucky. The registered enrollment target is 93 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02048917, a Phase 1 study of Lung Cancer and Head and Neck Cancer, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of routinely implementing an array of smoking cessation strategies for this patient population.
Primary Outcome
Seven day point prevalence of cigarette use confirmed with CO testing at eight weeks.
Conditions Studied
Interventions
- DRUG High Intensity Counseling + Long Acting NRT + PRN NRT
- DRUG High Intensity Counseling + bupropion + PRN NRT
- DRUG High Intensity Counseling + varenicline + PRN NRT
- DRUG High Intensity Counseling + Long Acting NRT
- DRUG High Intensity Counseling + bupropion
Study Locations (10)
Kentucky
- King's Daughters Medical Center - Ashland
- Hardin Memorial Health Cancer Care Center - Elizabethtown
- ARH Cancer Center - Hazard
- Kentucky Cancer Clinic - Hazard
- Lexington Veterans Affair Medical Center - Lexington
- University Of Kentucky, Markey Cancer Center - Lexington
- University of Louisville, James Graham Brown Cancer Center - Louisville
- St. Claire Regional Medical Center - Morehead
- Owensboro Health - Owensboro
West Virginia
- St. Mary's Medical Center - Huntington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-07-22 |
| Est. Completion | 2019-05-15 |
| Phase | Phase 1 |
What the finished NCT02048917 record still lists
NCT02048917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which High Intensity Counseling + Long Acting NRT + PRN NRT is the first listed.
NCT02048917 lists 10 locations in 2 states (Kentucky, West Virginia).
Frequently Asked Questions
What is clinical trial NCT02048917 about?
NCT02048917 is a clinical study titled "Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies". The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of r...
What is the current status of trial NCT02048917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2014-07-22. Estimated completion is 2019-05-15.
What conditions does trial NCT02048917 study?
This clinical trial studies the following conditions: Lung Cancer, Head and Neck Cancer.
What interventions are being tested in trial NCT02048917?
The interventions under investigation include: High Intensity Counseling + Long Acting NRT + PRN NRT (DRUG), High Intensity Counseling + bupropion + PRN NRT (DRUG), High Intensity Counseling + varenicline + PRN NRT (DRUG), High Intensity Counseling + Long Acting NRT (DRUG), High Intensity Counseling + bupropion (DRUG).
Who is sponsoring clinical trial NCT02048917?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02048917 being conducted?
This trial has 10 study locations across Kentucky, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02048917's enrollment target sits among peer trials
93 202nd of 409 higher than 207 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI